# BIOCRYST PHARMACEUTICALS, INC. (BCRX) FY2026 Q2 Balance Sheet

- Company: BIOCRYST PHARMACEUTICALS, INC. (BCRX)
- Period: As of 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-05, accession number 0001628280-26-053300
- Page: https://plicit.ai/financials/bcrx/fy2026-q2-balance-sheet
- Chart image: https://plicit.ai/charts/bcrx-fy2026-q2-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 557,851,000 US dollars
- **Current assets**: 484,683,000 US dollars
- **Non-current assets**: 73,168,000 US dollars
- **Liabilities**: 1,012,140,000 US dollars
- **Current liabilities**: 208,846,000 US dollars
- **Non-current liabilities**: 803,294,000 US dollars
- **Equity**: negative 454,289,000 US dollars
- **Short-term investments**: 197,601,000 US dollars
- **Cash and cash equivalents**: 154,972,000 US dollars
- **Trade receivables**: 110,757,000 US dollars
- **Prepaid expenses and other current assets**: 14,818,000 US dollars
- **Inventory, net**: 6,056,000 US dollars
- **Restricted cash**: 479,000 US dollars
- **Long-term inventory, net**: 31,945,000 US dollars
- **Other assets**: 19,557,000 US dollars
- **Right of use assets, net**: 12,608,000 US dollars
- **Property and equipment, net**: 9,058,000 US dollars
- **Long-term investments**: 0 US dollars
- **Accrued expenses**: 121,895,000 US dollars
- **Royalty financing obligations**: 43,808,000 US dollars
- **Share-based liability**: 16,360,000 US dollars
- **Deferred revenue**: 12,320,000 US dollars
- **Accounts payable**: 11,459,000 US dollars
- **Operating lease liabilities**: 1,912,000 US dollars
- **Finance lease liabilities**: 1,092,000 US dollars
- **Secured term loan**: 395,400,000 US dollars
- **Royalty financing obligations**: 382,981,000 US dollars
- **Deferred revenue**: 13,461,000 US dollars
- **Operating lease liabilities**: 10,603,000 US dollars
- **Finance lease liabilities**: 849,000 US dollars
- **Additional paid-in capital**: 1,693,282,000 US dollars
- **Common stock, $0.01 par value; shares authorized - 450,000; shares issued and outstanding – 255,265 at June 30, 2026 and 213,060 at December 31, 2025**: 2,553,000 US dollars
- **Preferred stock, $0.01 par value; shares authorized - 5,000; no shares issued and outstanding at June 30, 2026 and December 31, 2025**: 0 US dollars
- **Accumulated deficit**: negative 2,149,596,000 US dollars
- **Accumulated other comprehensive (loss) income**: negative 528,000 US dollars

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.